{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:41:44Z","timestamp":1792611704630,"version":"4.5.0"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>We report the case of a 25-year-old pregnant woman who was diagnosed with aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) at 19 weeks of gestation. During the acute stage of the disease, she was treated with high-dose prednisone pulse therapy. Beginning in the fourth week after disease onset, satralizumab was introduced as an adjunctive therapy, which enabled the progressive reduction and eventual discontinuation of corticosteroids. Subsequent follow-up showed marked improvement in visual field defect, successful spontaneous delivery, stable maternal condition, and transient early neonatal complications with favorable short-term recovery. This represents the first reported case in China of a patient diagnosed with AQP4 + NMOSD during pregnancy who was treated with satralizumab. This case provides additional clinical evidence to inform therapeutic decision-making for NMOSD occurring in pregnancy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1833243","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:11Z","timestamp":1779342191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Man","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuneng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106568","article-title":"Family planning in neuromyelitis optica spectrum disorder","volume":"101","author":"Shalaby","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0313-y","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations","volume":"16","author":"Mao-Draayer","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200124","article-title":"International Delphi consensus on the management of AQP4-IgG+ NMOSD: Recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Leite","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241283648","article-title":"Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: A case report","volume":"31","author":"Tommaso","year":"2025","journal-title":"Mult Scler"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1322412","DOI":"10.21203\/rs.3.rs-3368889\/v1","article-title":"Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report","volume":"14","author":"Yoshida","year":"2023","journal-title":"Front Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55010","article-title":"Successful childbirth during satralizumab treatment in neuromyelitis optica spectrum disorder","volume":"16","author":"Nakashima","year":"2024","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5870-25","article-title":"Safe childbirth in a patient with neuromyelitis optica spectrum disorder treated with satralizumab","volume":"65","author":"Yaguchi","year":"2025","journal-title":"Intern Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1514687","article-title":"Case report: Satralizumab as an adjunctive therapy for AQP-4 antibody and MOG antibody dual-negative optic neuritis in a third-trimester pregnancy case","volume":"11","author":"Sun","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41598-025-88624-x","article-title":"Insights into neuromyelitis optica spectrum disorder and pregnancy from a single-center study in Thailand","volume":"15","author":"Budtarad","year":"2025","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/jnnp-2020-323982","article-title":"Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors","volume":"92","author":"Wang","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1833243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:13Z","timestamp":1779342193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1833243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":10,"alternative-id":["10.3389\/fimmu.2026.1833243"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1833243","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1833243"}}